Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bayer (DE:BAYN)
XETRA:BAYN
Bayer (BAYN) Stock Price & Analysis
468 Followers
BAYN Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€24.86 - €54.73
Previous Close€28.58
Volume460.30K
Average Volume (3M)4.37M
Market Cap
€28.08B
Enterprise Value€59.40B
Total Cash (Recent Filing)€10.15B
Total Debt (Recent Filing)€41.32B
Price to Earnings (P/E)-9.0
Beta0.84
Next Earnings
Aug 06, 2024Last Dividend Ex-Date
Apr 29, 2024Dividend Yield0.38%
Share Statistics
EPS (TTM)-3.17
Shares Outstanding982,424,082
10 Day Avg. Volume3,479,893
30 Day Avg. Volume4,366,626
Standard Deviation0.10
R-Squared0.22
Alpha-0.00793
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.69Price Target Upside10.86% Upside
Rating ConsensusHold
Number of Analyst Covering15
Bayer News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnalyst highlights the company's financial strength as EBITDA was higher than expected, largely due to impressive Crop Science margins and stronger EPS attributed to reduced financial costs.
Market PerformanceAnalyst points to robust market performance with Consumer Health achieving double-digit organic top-line growth and an impressive EBITDA margin in the fourth quarter.
Strategic InitiativesThe company's strategic restructuring, including commendable organisational changes and a significant cost savings plan under CEO Bill Anderson, is seen as a major positive catalyst.
Bears Say
Competitive LandscapePharma's outlook remains cautious with expected flat organic growth and a forecasted significant drop in Xarelto revenues due to competition from generic products.
Financial PerformanceQ1 with toughest year-on-year comparison shows a potential slow start, with significant decline in earnings before interest, taxes, depreciation, and amortization (EBITDA) due to challenges in Crop Science and increased expenses.
Sector ChallengesConsumer Health faces a tough comparison to a strong previous season and is likely to experience a decline in EBITDA due to increased marketing investments and material foreign exchange headwind.
---
Options Prices
Currently, No data available
---
Ownership Overview
<0.01% Insiders
15.58% Mutual Funds
11.86% Other Institutional Investors
72.57% Public Companies and
Individual Investors
BAYN FAQ
What was Bayer’s price range in the past 12 months?
Bayer lowest stock price was €24.86 and its highest was €54.73 in the past 12 months.
What is Bayer’s market cap?
Currently, no data Available
When is Bayer’s upcoming earnings report date?
Bayer’s upcoming earnings report date is Aug 06, 2024 which is in 79 days.
How were Bayer’s earnings last quarter?
Bayer released its earnings results on May 14, 2024. The company reported €2.82 earnings per share for the quarter, beating the consensus estimate of €2.318 by €0.502.
Is Bayer overvalued?
According to Wall Street analysts Bayer’s price is currently Undervalued.
Does Bayer pay dividends?
Bayer pays a Annually dividend of €0.11 which represents an annual dividend yield of 0.38%. See more information on Bayer dividends here
What is Bayer’s EPS estimate?
Bayer’s EPS estimate is €1.
How many shares outstanding does Bayer have?
Bayer has 982,424,100 shares outstanding.
What happened to Bayer’s price movement after its last earnings report?
Bayer reported an EPS of €2.82 in its last earnings report, beating expectations of €2.318. Following the earnings report the stock price went down -0.545%.
Which hedge fund is a major shareholder of Bayer?
Currently, no hedge funds are holding shares in DE:BAYN
---
Bayer Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.33%
12-Months-Change
Fundamentals
Return on Equity
-8.16%
Trailing 12-Months
Asset Growth
-4.13%
Trailing 12-Months
Company Description
Bayer
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides just over half of the company's sales and includes pharmaceutical drugs as well as vitamins. The company has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.
---
BAYN Stock 12 Month Forecast
Average Price Target
€31.69
▲(10.86% Upside)
Technical Analysis
Best Analysts Covering BAYN
1 Year
1 Year Success Rate
10/25 ratings generated profit
1 Year Average Return
-9.15%
reiterated a buy rating 2 months ago
Copying Peter Spengler's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -9.15% per trade.
---